BioVie Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
BioVie Inc. (BIVI) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $18.22 thousand for the 6-month period ending 2022-12-31, per its 10-Q filed 2023-02-10.
Discontinued › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2023-02-10
- BioVie Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-12-31 was $9.23K.
- BioVie Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-09-30 was $8.98K.
- BioVie Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $8.04K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2022-12-31 | $9.23K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-10 | $18.22K 10-Q · filed 2023-02-10 | ||
| 2022-09-30 | $8.98K 10-Q · filed 2022-11-04 | -$77.00 10-Q · filed 2022-05-11 | ||
| 2022-06-30 | $8.04K 10-K · filed 2022-09-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |